1.Efficacy of Wuda Granule on Recovery of Gastrointestinal Function after Laparoscopic Bowel Resection: A Randomized Double-Blind Controlled Trial.
Hai-Ping ZENG ; Li-Xing CAO ; De-Chang DIAO ; Ze-Huai WEN ; Wen-Wei OUYANG ; Ai-Hua OU ; Jin WAN ; Zhi-Jun PENG ; Wei WANG ; Zhi-Qiang CHEN
Chinese journal of integrative medicine 2024;30(12):1059-1067
OBJECTIVE:
To evaluate the efficacy and safety of Wuda Granule (WDG) on recovery of gastrointestinal function after laparoscopic bowel resection in the setting of enhanced recovery after surgery (ERAS)-based perioperative care.
METHODS:
A total of 108 patients aged 18 years or older undergoing laparoscopic bowel resection with a surgical duration of 2 to 4.5 h were randomly assigned (1:1) to receive either WDG or placebo (10 g/bag) twice a day from postoperative days 1-3, combining with ERAS-based perioperative care. The primary outcome was time to first defecation. Secondary outcomes were time to first flatus, time to first tolerance of liquid or semi-liquid food, gastrointestinal-related symptoms and length of stay. Subgroup analysis of the primary outcome according to sex, age, tumor site, surgical time, histories of underlying disease or history of abdominal surgery was undertaken. Adverse events were observed and recorded.
RESULTS:
A total of 107 patients [53 in the WDG group and 54 in the placebo group; 61.7 ± 12.1 years; 50 males (46.7%)] were included in the intention-to-treat analysis. The patients in the WDG group had a significantly shorter time to first defecation and flatus [between-group difference -11.01 h (95% CI -20.75 to -1.28 h), P=0.012 for defecation; -5.41 h (-11.10 to 0.27 h), P=0.040 for flatus] than the placebo group. Moreover, the extent of improvement in postoperative gastrointestinal-related symptoms in the WDG group was significantly better than that in the placebo group (P<0.05). Subgroup analyses revealed that the benefits of WDG were significantly superior in patients who were male, or under 60 years old, or surgical time less than 3 h, or having no history of basic disease or no history of abdominal surgery. There were no serious adverse events.
CONCLUSION
The addition of WDG to an ERAS postoperative care may be a viable strategy to enhance gastrointestinal function recovery after laparoscopic bowel resection surgery. (Registry No. ChiCTR2100046242).
Humans
;
Laparoscopy/adverse effects*
;
Male
;
Female
;
Middle Aged
;
Double-Blind Method
;
Recovery of Function
;
Drugs, Chinese Herbal/adverse effects*
;
Treatment Outcome
;
Gastrointestinal Tract/physiopathology*
;
Defecation
;
Aged
;
Intestines/physiopathology*
2.Sanitation status of centralized air ventilation system of public places in Putuo District, Shanghai, 2014-2018
Hua GONG ; Chun-yan QIAN ; Xu-fang QUAN ; Hai-peng DIAO
Shanghai Journal of Preventive Medicine 2020;32(4):299-
Objective To investigate the sanitation status of centralized air ventilation system in Putuo District of Shanghai, to analyze correlation between different indexes and to provide basis for improving the health status of public places and strengthening health supervision. Methods According to the requirements of WS 394-2012
3.AntiEGFRnano inhibites proliferation and migration of estrogen-dependent Ishikawa cells of human endometrial cancer cell line.
Zhen-yu DIAO ; Wu-guang LU ; Peng CAO ; Yun-long HU ; Xing ZHOU ; Ping-ping XUE ; Li SHEN ; Hai-xiang SUN
Acta Pharmaceutica Sinica 2012;47(10):1341-1346
Nanobody is a kind of antibody from camel, which misses light chain. Nanobody has the same antigen binding specificity and affinity as mAb. Moreover, because of its small molecular weight, high stability and easy preparation, nanobody has great value of biomedical applications. In this study, we successfully prepared highly pure antiEGFR nanobody in E.coli using genetic engineering techniques. Cell proliferation assay (CCK-8 assay) and migration experiments (cell scratch test and Transwell assay) indicated that the recombinant antiEGFRnano can significantly inhibit the proliferation and migration of endometrial cancer cells. These results provide a new way of thinking and methods for EGFR-targeted therapy of endometrial cancer.
Adenocarcinoma
;
metabolism
;
pathology
;
Amino Acid Sequence
;
Base Sequence
;
Cell Line, Tumor
;
Cell Movement
;
drug effects
;
Cell Proliferation
;
drug effects
;
Endometrial Neoplasms
;
metabolism
;
pathology
;
Escherichia coli
;
metabolism
;
Estrogens
;
metabolism
;
Female
;
Genetic Vectors
;
Humans
;
Plasmids
;
Receptor, Epidermal Growth Factor
;
genetics
;
immunology
;
Recombinant Proteins
;
metabolism
;
Single-Domain Antibodies
;
genetics
;
pharmacology

Result Analysis
Print
Save
E-mail